Matinas BioPharma Holdings Inc (MTNB)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $881,570
Last updated: Nov 17, 2026 at 4:10 PM ET
Matinas BioPharma Holdings Inc (MTNB) Statistics
Matinas BioPharma Holdings (MTNB) has a market cap of $881,570. It holds $1.94M more cash than debt, 219.49% of its market cap.
Total Valuation
| Market Cap | $881,570 |
|---|---|
| Latest price (Nov 17, 2026) | $0.88 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/E Ratio | 0.9x |
|---|---|
| P/B Ratio | 0.3x |
| P/TBV Ratio | 1.5x |
Price Statistics
The stock is down 95.17% over 52 weeks and trades 57.69% below its 50-day average.
| Beta (1Y) | 0.26 |
|---|---|
| 52-Week Change | -95.17% |
| 1-Month Change | -46.70% |
| 3-Month Change | -75.53% |
| 6-Month Change | -89.41% |
| 5-Year Change | -99.82% |
| 10-Year Change | -99.86% |
| Total Return (1Y) | -95.17% |
| Total Return (3Y CAGR) | -82.86% |
| Total Return (5Y CAGR) | -74.36% |
| Max Drawdown (1Y) | -95.00% |
| Max Drawdown (3Y) | -99.68% |
| Sharpe Ratio (1Y) | -2.28 |
| Correlation with SPY (1Y) | 0.03 |
| 50-Day Average | $2.08 |
| 200-Day Average | $6.46 |
| 52-Week Range | $0.81 to $17.40 |
| RSI (14 Days) | 26.9 |
| Average Volume (20 Days) | 55.96K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.78x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.78x |
|---|---|
| Quick Ratio | 1.78x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on invested capital is -187.86% and return on equity is -236.48% over the last 12 months.
| Return on Equity (ROE) | -236.48% |
|---|---|
| Return on Assets (ROA) | -158.12% |
| Return on Invested Capital (ROIC) | -187.86% |
Scores
MTNB has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | $85.00K |
| Operating Income | -$6.83M |
| Pretax Income | -$6.93M |
| Net Income | -$6.92M |
| EBITDA | -$6.45M |
| Reported EPS (TTM) | $1.01 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 66.89% of the $4.38M in total assets.
| Cash and Equivalents | $1.94M |
|---|---|
| Total Debt | $1.00K |
| Net Cash | $1.94M |
| Net Cash Per Share | $1.74 |
| Working Capital | $926.00K |
| Shareholder Equity | $2.93M |
| Book Value Per Share | $2.63 |
| Tangible Book Value | $668.00K |
| Tangible Book Per Share | $0.60 |
| Total Assets | $4.38M |
| Total Liabilities | $1.45M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$6.56M |
|---|---|
| FCF Per Share | -$6.70 |
| Depreciation and Amortization | $515.00K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
MTNB does not pay a dividend.
| Earnings Yield | 111.11% |
|---|---|
| Buyback Yield | -286.46% |
| Shareholder Yield | -286.46% |
Stock Splits
The last split was a 1-for-15 reverse split on Sep 28, 2026.
| Last Split Date | Sep 28, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About MTNB
What is MTNB's market cap?
Matinas BioPharma Holdings has a market cap of $881,570.
What is MTNB's P/E ratio?
Matinas BioPharma Holdings has a trailing P/E ratio of 0.9x.
How many shares of MTNB are outstanding?
Matinas BioPharma Holdings has 1.11M shares outstanding.
Does MTNB pay a dividend?
No. Matinas BioPharma Holdings does not pay a dividend.
How much debt does MTNB have?
Matinas BioPharma Holdings has $1.00K of total debt and $1.94M of cash and equivalents, a net cash position of $1.94M.
MTNB pages: Overview, Charting, Earnings, Financials, Statistics, Competitors